Important considerations before Initiation of Ibrutinib Treatment

Nahla A M Hamed
Additional contact information
Nahla A M Hamed: Professor of Hematology, Faculty of Medicine, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2019, vol. 15, issue 1, 9-11

Abstract: Ibrutinib is a Bruton’s tyrosine kinase inhibitor which interferes with signaling through the B-cell receptor pathway. Ibrutinib is metabolized via cytochrome P450 enzyme 3A. Potential drug interactions need to be considered with its use. Ibrutinib is generally well tolerated. Diarrhea and skin rashes are relatively common, often transient, and can resolve with no specific management. Bleeding, atrial fibrillation, arthritis and arthralgia, fatigue, cytopenias, and infections are more serious but less common drug specific complications.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555902.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555902.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:15:y:2019:i:1:p:9-11

DOI: 10.19080/CTOIJ.2019.15.555902

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().